Perspective Therapeutics (CATX) said Friday its updated interim findings from phase 1/2a study of radiopharmaceutical therapy for advanced neuroendocrine tumors have shown continued patient safety and early signs of efficacy, supporting further dose-finding research.
Nine patients with unresectable or metastatic somatostatin receptor type 2-expressing tumors completed treatment as of Jan. 10, the company said.
Perspective Therapeutics said no dose-limiting toxicities or severe adverse events emerged, and there was no reported decline in renal function, adding that hematologic side effects, such as reduced lymphocyte counts and mild anemia, were limited to grades 1 and 2.
The trial is ongoing at multiple sites for patients who have not previously received radiopharmaceutical therapy and whose disease progressed in the past year, it added.
Shares of the company were up about 4.1% in recent trading.
Price: 3.78, Change: +0.15, Percent Change: +4.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.